IOL (Free subscription) | 11/27/2008
US drug giant Pfizer has said that out-of-court negotiations with Nigeria seem to be heading on a right direction.
bizjournals (Free subscription) | 11/26/2008
Pfizer Inc. won full FDA approval today for its next-generation HIV drug Selzentry — a move expected to push sales of a test from South San Francisco’s Monogram Biosciences Inc. (NASDAQ: MGRMD). (MGRMD) (PFE)
The East Bay Business Times (Free subscription) | 11/26/2008
Pfizer Inc. won full FDA approval today for its next-generation HIV drug Selzentry — a move expected to push sales of a test from South San Francisco’s Monogram Biosciences Inc. (NASDAQ: MGRMD). (MGRMD) (PFE)
Daily Mail News (Free subscription) | 11/28/2008
An investigation of major pharmaceutical companies - including Pfizer Inc., GlaxoSmithKline and Sanofi-Aventis - showed they had blocked or delayed generic drugs from entering the market to prevent losing revenue on their more profitable drugs, the European Commission said.
Miami Herald (Free subscription) | 11/28/2008
... to prevent losing revenue from profitable drugs.The investigation covered companies including Pfizer Inc., GlaxoSmithKline and Sanofi Aventis. The EU executive said Friday they used costly legal action to stall generic drug companies from making their own versions of medicines once patents had expired. It says they launched disputes, lawsuits and multiple patent applications for the...
kansascity.com (Free subscription) | 11/28/2008
BRUSSELS, Belgium European patients had to pay some euro3 billion ($3.87 billion) more for medicines in 2000-2007 because pharmaceutical companies deliberately stalled the sale of cheaper generic versions, EU antitrust regulators said Friday.
An investigation of major pharmaceutical companies - including Pfizer Inc., GlaxoSmithKline and Sanofi-Aventis - showed they had blocked or...
kansascity.com (Free subscription) | 11/28/2008
... prevent losing revenue from profitable drugs.
The investigation covered companies including Pfizer Inc., GlaxoSmithKline and Sanofi Aventis.
The EU executive said Friday they used costly legal action to stall generic drug companies from making their own versions of medicines once patents had expired. It says they launched disputes, lawsuits and multiple patent applications...
Seattle Times (Free subscription) | 11/28/2008
An investigation of major pharmaceutical companies - including Pfizer Inc., GlaxoSmithKline and Sanofi Aventis - showed they had blocked or delayed generic drugs from entering the market to prevent losing revenue on their more profitable drugs, the European Commission said.
Seattle Post-Intelligencer (Free subscription) | 11/28/2008
... to prevent losing revenue from profitable drugs.The investigation covered companies including Pfizer Inc., GlaxoSmithKline and Sanofi Aventis.The EU executive said Friday they used costly legal action to stall generic drug companies from making their own versions of medicines once patents had expired. It says they launched disputes, lawsuits and multiple patent applications for the...
San Fransisco Chronicle (Free subscription) | 11/28/2008
An investigation of major pharmaceutical companies — including Pfizer Inc., GlaxoSmithKline and Sanofi Aventis — showed they had blocked or delayed generic drugs from entering the market to prevent losing revenue on their more profitable drugs, the European Commission said.
Legal Radar (Free subscription) | 11/27/2008
... based attorney representing some of the women, stated that the trial did not include Wyeth and Pfizer Inc., the two largest manufacturers of HRT drugs. Bristol- Myers and Solvay face the most claims over their HRT drugs, more so than Wyeth or Pfizer. The trial which has been going on for three months will be presided over by judge William Wilson of the U.S. District Court.
The Philadelphia Business Journal (Free subscription) | 11/24/2008
David R. King was named chairman of Diasome Pharmaceuticals Inc. on Monday
Business Wire (Free subscription) | 11/26/2008
... market value, volume, expenditure and consumption data by market, segment and subsegment - Includes company and brand share data by categories Key reasons to purchase this title - Discover the major quantitative trends affecting the OTC Healthcare markets - Understand consumers consumption and expenditure patterns - Understand the future direction of the market with reliable historical data and...
Boston Globe (Free subscription) | 11/25/2008
... has not yet taken a stance on the issue. However, the group -- which represents Merck & Co. Inc., Pfizer Inc., Wyeth and other drugmakers -- supported adding the language about side effects to print ads.TV promotions have become a cornerstone of the pharmaceutical business since regulators opened the floodgate a decade ago. Companies spent roughly $3.5 billion on commercials...
Seattle Times (Free subscription) | 11/25/2008
... America has not yet taken a stance on the issue. However, the group - which represents Merck & Co. Inc., Pfizer Inc., Wyeth and other drugmakers - supported adding the language about side effects to print ads.TV promotions have become a cornerstone of the pharmaceutical business since regulators opened the floodgate a decade ago. Companies spent roughly $3.5 billion on commercials...
